These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
576 related articles for article (PubMed ID: 34166623)
1. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Wang R; Zhang Q; Ge J; Ren W; Zhang R; Lan J; Ju B; Su B; Yu F; Chen P; Liao H; Feng Y; Li X; Shi X; Zhang Z; Zhang F; Ding Q; Zhang T; Wang X; Zhang L Immunity; 2021 Jul; 54(7):1611-1621.e5. PubMed ID: 34166623 [TBL] [Abstract][Full Text] [Related]
2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620 [TBL] [Abstract][Full Text] [Related]
4. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion. Xue S; Han Y; Wu F; Wang Q Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025 [TBL] [Abstract][Full Text] [Related]
5. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142 [TBL] [Abstract][Full Text] [Related]
6. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. Alenquer M; Ferreira F; Lousa D; Valério M; Medina-Lopes M; Bergman ML; Gonçalves J; Demengeot J; Leite RB; Lilue J; Ning Z; Penha-Gonçalves C; Soares H; Soares CM; Amorim MJ PLoS Pathog; 2021 Aug; 17(8):e1009772. PubMed ID: 34352039 [TBL] [Abstract][Full Text] [Related]
7. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843 [TBL] [Abstract][Full Text] [Related]
8. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
9. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. Villoutreix BO; Calvez V; Marcelin AG; Khatib AM Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580 [TBL] [Abstract][Full Text] [Related]
10. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856 [TBL] [Abstract][Full Text] [Related]
11. Antibody evasion by the P.1 strain of SARS-CoV-2. Dejnirattisai W; Zhou D; Supasa P; Liu C; Mentzer AJ; Ginn HM; Zhao Y; Duyvesteyn HME; Tuekprakhon A; Nutalai R; Wang B; López-Camacho C; Slon-Campos J; Walter TS; Skelly D; Costa Clemens SA; Naveca FG; Nascimento V; Nascimento F; Fernandes da Costa C; Resende PC; Pauvolid-Correa A; Siqueira MM; Dold C; Levin R; Dong T; Pollard AJ; Knight JC; Crook D; Lambe T; Clutterbuck E; Bibi S; Flaxman A; Bittaye M; Belij-Rammerstorfer S; Gilbert SC; Carroll MW; Klenerman P; Barnes E; Dunachie SJ; Paterson NG; Williams MA; Hall DR; Hulswit RJG; Bowden TA; Fry EE; Mongkolsapaya J; Ren J; Stuart DI; Screaton GR Cell; 2021 May; 184(11):2939-2954.e9. PubMed ID: 33852911 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012 [TBL] [Abstract][Full Text] [Related]
14. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA Elife; 2021 Aug; 10():. PubMed ID: 34435953 [TBL] [Abstract][Full Text] [Related]
15. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2. Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530 [TBL] [Abstract][Full Text] [Related]
16. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Gobeil SM; Janowska K; McDowell S; Mansouri K; Parks R; Stalls V; Kopp MF; Manne K; Li D; Wiehe K; Saunders KO; Edwards RJ; Korber B; Haynes BF; Henderson R; Acharya P Science; 2021 Aug; 373(6555):. PubMed ID: 34168071 [TBL] [Abstract][Full Text] [Related]
17. AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance. Raisinghani N; Alshahrani M; Gupta G; Verkhivker G Viruses; 2024 Sep; 16(9):. PubMed ID: 39339934 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349 [TBL] [Abstract][Full Text] [Related]
19. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. Bayarri-Olmos R; Rosbjerg A; Johnsen LB; Helgstrand C; Bak-Thomsen T; Garred P; Skjoedt MO J Biol Chem; 2021; 296():100536. PubMed ID: 33716040 [TBL] [Abstract][Full Text] [Related]